TAK-677 (Dainippon/Takeda).
TAK-677 is a beta3-adrenergic agonist under development by Dainippon and Takeda for the potential treatment of non-insulin dependent diabetes and obesity. In March 2001, Takeda initiated a phase II trial in the US for Type II diabetes [411811], [416686], [423455]. By December 2001, the compound was also in phase II trials for obesity in the US, and Dainippon was conducting phase II studies in Japan for diabetes [458750].